Loading...
•
Dec 31, 2021
Allakos Q4 2021 Earnings Report
Allakos reported financial results for the fourth quarter and full year ended December 31, 2021.
Key Takeaways
Allakos reported a net loss of $94.4 million in the fourth quarter of 2021, compared to a net loss of $44.3 million in the same period in 2020. The company ended the quarter with $424.2 million in cash, cash equivalents and marketable securities.
Initiated a Phase 2 study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis in Q4 2021.
Reported topline data from the ENIGMA 2 Phase 3 study of lirentelimab in EG/EoD patients in Q4 2021.
Reported topline data from the KRYPTOS Phase 2/3 study of lirentelimab in EoE patients in Q4 2021.
Allakos ended Q4 2021 with $424.2 million in cash, cash equivalents and marketable securities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...